Actively Recruiting
Comparing Lower Protamine Doses to Reverse Heparin After Heart Surgery Using Cardiopulmonary Bypass
Led by Sohag University · Updated on 2026-05-05
195
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying different doses of protamine sulfate to reverse the effects of heparin anticoagulation after cardiopulmonary bypass in adult patients undergoing elective heart surgery. The study compares the usual protamine dose with two reduced doses to see if lower doses can safely reverse heparin while reducing side effects such as bleeding, platelet problems, and blood pressure changes. The trial is a multicenter, randomized, double-blind, controlled study led by Sohag University. Participants will be randomly assigned to receive one of three protamine-to-heparin dosing ratios the standard 1 mg protamine per 100 IU heparin, or reduced doses of 0.8 mg or 0.75 mg per 100 IU of heparin. Protamine sulfate will be given intravenously over 5 to 10 minutes at the end of cardiopulmonary bypass. The different dosing groups will allow comparison of the effects of protamine dose on heparin reversal and related outcomes. During the study, researchers will measure the activated clotting time ACT 5 minutes after protamine administration to assess heparin reversal. They will also monitor the need for additional protamine, bleeding after surgery, blood transfusions, protamine-related side effects, and any return to surgery for bleeding within 24 hours after surgery. The length of intensive care unit stay will also be recorded. Participants consent before surgery and will be followed closely during and shortly after their procedure.
CONDITIONS
Brief Title
Dose for Reversal of Heparin After Cardiopulmonary Bypass
Research Team
A
Asmaa S Farghaly, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here